February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial

Merck reported positive results from the Phase III trial of its non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (MK-1439) for the treatment of patients with HIV-1 infection, and NIH's NIAID initiated a Phase I trial of vaccine AGS-v …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news